GDF15 and myocardial infarction: In the PLATO (PLATelet inhibition and patient Outcomes) trial, GDF-15 was an independent risk factor for major bleeding across different bleeding locations, as well as for the composite endpoint of cardiovascular death, spontaneous myocardial infarction and stroke in ACS patients.